Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Prescriere limitată: Tratamentul sarcomului Kaposi (SK) corelat cu SIDA (SK-SIDA), la pacienţii cu număr mic de limfocite CD4 (< 200 limfocite CD4/mm
Yüklə 4,39 Mb.
|
| Prescriere limitată: Tratamentul sarcomului Kaposi (SK) corelat cu SIDA (SK-SIDA), la pacienţii cu număr mic de limfocite CD4 (< 200 limfocite CD4/mm3) şi cu afectare mucocutanată sau viscerală extinsă. Poate fi utilizat în chimioterapia sistemică de primă linie sau în chimioterapia de linia a doua la pacienţii cu SK-SIDA la care boala a avansat sau la pacienţii cu intoleranţă la tratament, la care s-a administrat anterior chimioterapie sistemică combinată, cuprinzând cel puţin două dintre următoarele chimioterapice: alcaloid de vinca, bleomicină şi doxorubicină standard (sau altă antraciclină).
L01DB01 DOXORUBICINUM CONC. PT. SOL. PERF. 2 mg/ml DOXORUBICIN "EBEWE" 2 mg/ml 2 mg/ml EBEWE PHARMA GMBH NFG. KG L01DB01 DOXORUBICINUM PULB. PT. SOL. PERF. 2 mg/ml SINDROXOCIN 2 mg/ml 2 mg/ml ACTAVIS S.R.L. L01DB01 DOXORUBICINUM SOL. INJ. 2 mg/ml DOXORUBICIN TEVA 2 mg/ml 2 mg/ml TEVA PHARMACEUTICALS S.R.L.
ADRIBLASTINA RD 50 mg 50 mg ACTAVIS S.R.L. ________________________________________________________________________________
| 733 |L01DB03| EPIRUBICINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01DB03 EPIRUBICINUM LIOF. PT. SOL. INJ. 10 mg EPISINDAN 10 mg 10 mg ACTAVIS S.R.L. FARMORUBICIN RD 10 mg 10 mg ACTAVIS S.R.L. L01DB03 EPIRUBICINUM CONC. PT. SOL. INJ. 2 mg/ml EPIRUBICIN "EBEWE" 2 mg/ml 2 mg/ml EBEWE PHARMA GMBH NFG. KG L01DB03 EPIRUBICINUM LIOF. PT. SOL. INJ. 50 mg EPISINDAN 50 mg 50 mg ACTAVIS S.R.L. FARMORUBICIN(R) RD 50 mg 50 mg ACTAVIS S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 734 |L01DB06| IDARUBICINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01DB06 IDARUBICINUM CAPS. 10 mg ZAVEDOS 10 mg PFIZER EUROPE MA EEIG
ZAVEDOS 5 mg 5 mg PFIZER EUROPE MA EEIG ________________________________________________________________________________
| 735 |L01DB07| MITOXANTRONUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01DB07 MITOXANTRONUM CONC. PT. SOL. PERF. 2 mg/ml MITOXANTRONE TEVA 2 mg/ml 2 mg/ml TEVA PHARMACEUTICALS SRL
NOVANTRONE 20 mg/10 ml WYETH LEDERLE PHARMA GMBH L01DB07 MITOXANTRONUM CONC. PT. SOL. INJ. 2 mg/ml ONKOTRONE 2 mg/ml BAXTER ONCOLOGY GMBH ________________________________________________________________________________
| 736 |L01DC01| BLEOMYCINUM SULFAS | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01DC01 BLEOMYCINUM SULFAS LIOF. PT. SOL. INJ. 15 mg BLEOCIN 15 mg EURO NIPPON KAYAKU GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 738 |L01XA01| CISPLATINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01XA01 CISPLATINUM LIOF. PT. SOL. PERF. 10 mg SINPLATIN 10 mg 10 mg ACTAVIS S.R.L.
CISPLATIN "EBEWE" 10 mg/20 ml 10 mg/20 ml EBEWE PHARMA GMBH NFG. KG CISPLATIN TEVA 10 mg/20 ml 10 mg/20 ml TEVA PHARMACEUTICALS S.R.L.
SINPLATIN 1 mg/1 ml 1 mg/1 ml ACTAVIS S.R.L.
CISPLATIN "EBEWE" 25 mg/50 ml 25 mg/50 ml EBEWE PHARMA GMBH NFG. KG L01XA01 CISPLATINUM LIOF. PT. SOL. PERF. 50 mg SINPLATIN 50 mg 50 mg ACTAVIS S.R.L. L01XA01 CISPLATINUM CONC. PT. SOL. PERF. 50 mg/100 ml CISPLATIN "EBEWE" 50 mg/100 ml EBEWE PHARMA GMBH NFG. KG 50 mg/100 ml ________________________________________________________________________________ ______________________________________________________________________________ | 739 |L01XA02| CARBOPLATINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01XA02 CARBOPLATINUM CONC. PT. SOL. PERF. 10 mg/ml CARBOPLATIN "EBEWE" 10 mg/ml 10 mg/ml EBEWE PHARMA GES.M.B.H. NFG KG
CARBOPLATIN ACTAVIS 10 mg/ml 10 mg/ml ACTAVIS S.R.L. CARBOPLATIN TEVA 10 mg/ml 10 mg/ml TEVA PHARMACEUTICALS S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 740 |L01XA03| OXALIPLATINUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|